The Five Most Promising Drugs Entering Phase II Trials
* CPP-109, (addiction to cocaine and methamphetamine), Catalyst
Pharmaceuticals
* intranasal insulin formulation, (diabetes), Nastech
* LCP-AtorFen, (cholesterol), Life Cycle
* EC-145, (ovarian and lung cancer), Endocyte
* TG-100801, (AMD, diabetic macular edemia, diabetic retinopathy),
TargeGen
The Five Most Promising Drugs Entering Phase I Trials
* affitope AD-01, (Alzheimer's disease), AFFiRiS
* MEM-63908, (Alzheimer's disease, CNS disorders), Memory/Roche
* TC-5619, (schizophrenia, depression), Targacept
* RDEA-806, (HIV infection), Ardea Biosciences
* APD-791, (arterial thrombosis), Arena Pharmaceuticals
About This Quarterly Report:
Data for this report was compiled and analyzed using Thomson Pharma(R), a comprehensive global pharmaceutical information solution that covers the entire drug discovery and development pipeline. Its competitive intelligence and strategic data can justify and speed decision-making, facilitate more focused collaboration, and encourage innovation.
For a copy of the full report with analysis, visit: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/tp_qr_jul- sep2007.pdf Due to length of URL, please cut and paste into browser
About The Thomson Corporation
The Thomson Corporation (http://www.thomson.com) is a global leader in
providing essential electronic workflow solutions to business and
professional customers. With operational headquarters in Stamford, CT,
Thomson provides value-added information, software tools and applications
to professionals in the fields of law, tax, accounting, financial services,
scientific research, and healthcare. The corporation's common shares are
listed on the New York and
'/>"/>
| SOURCE Thomson Scientific Copyright©2007 PR Newswire. All rights reserved |